Introduction {#Sec1}
============

Diabetes mellitus is characterized by chronic hyperglycemia and other metabolic abnormalities due to insufficient action of insulin. Diabetes is classified as type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) based on its etiology. The pathogenesis of T2DM involves a combination of impaired insulin secretion from pancreatic β cells and insulin resistance. Hyperglycemia develops from this insulin-insufficient state, often presenting early as postprandial hyperglycemia.

The goal of treatment in diabetes is to control hyperglycemia to near-normal glucose levels. This is important to prevent progression to microvascular complications, as well as to macrovascular complications such as myocardial infarction. Postprandial hyperglycemia has recently been reported to be an independent risk factor for arteriosclerotic disease \[[@CR1]\]. The Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe (DECODE) study reported a positive correlation between 2 h values on an oral glucose tolerance test (OGTT) and overall mortality rates \[[@CR2]\]. The Funagata study, conducted among residents of Funagata in Yamagata Prefecture, reported that impaired fasting glucose (IFG), defined as an elevation of fasting plasma glucose (FPG), but with a normal 2 h OGTT value, was not a risk factor for cardiovascular death \[[@CR3]\]. Large-scale clinical studies, including the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) study \[[@CR4]\], the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study \[[@CR5]\] and the Veterans Affairs Diabetes Trial (VADT) \[[@CR6]\], showed that glycemic control based on glycated hemoglobin (HbA1c) levels alone does not reduce macrovascular disease. In addition to glycemic control using HbA1c as a marker, high-quality glycemic control focusing also on postprandial plasma glucose (PPG) levels is necessary.

Mitiglinide is a rapid- and short-acting insulinotropic sulfonylurea receptor (SUR) ligand, a benzylsuccinic acid derivative \[[@CR7]--[@CR9]\], which improves postprandial hyperglycemia in particular. In addition to mitiglinide, repaglinide and nateglinide are currently in clinical use as insulinotropic SUR ligands.

The present study evaluated the long-term efficacy and safety of adding mitiglinide (mitiglinide calcium hydrate (Glufast^®^ tablets; Kissei Pharmaceutical Co. Ltd; Matsumoto, Japan) in Japanese patients with diabetes inadequately controlled with a dipeptidyl peptidase-4 (DPP-4) inhibitor or biguanide monotherapy.

Materials and Methods {#Sec2}
=====================

This study was conducted between March 2011 and August 2012 at 13 medical institutions in Japan. All procedures were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients before inclusion into the study.

Patients {#Sec3}
--------

Subjects were adult T2DM patients without adequate glycemic control. Inclusion criteria were: HbA1c 6.9% to \<9.4%; 1 or 2 h PPG ≥200 mg/dL on a meal tolerance test; and a fixed dosage and administration of either a DPP-4 inhibitor or biguanide during at least 8 weeks before starting mitiglinide. Exclusion criteria were: patients with history of treatment with high-dose sulfonylurea (SU) within 24 weeks (168 days) of starting the observation period (week 4); patients requiring insulin therapy; patients with severe diabetic complications (including neuropathy, retinopathy, and nephropathy), severe liver disease, renal dysfunction, hypertension, or heart disease.

Study Design {#Sec4}
------------

This study was a multicenter, open label, long-term clinical trial. Patient eligibility was assessed during a 4-week observation period. Patients were seen as outpatients every 4 weeks after starting the study, and treatment was continued for 52 weeks.

During the 4-week observation period, a fixed dose of DPP-4 inhibitor or biguanide was administered orally. Eligible patients who met the inclusion criteria during the observation period then continued with the DPP-4 inhibitor or biguanide at the same dosage and additionally received mitiglinide 10 mg three times a day orally (t.i.d PO) immediately (within 5 min) before each meal. Thereafter, if after 12 weeks of continuous administration HbA1c did not reach the target value \[\<7.4% if ≥7.4% at the start of administration (week 0) or \<6.9% if \<7.4% at week 0\], the dosage of mitiglinide could be increased to 20 mg t.i.d from week 16 to attempt to gain further improvement. However, if the physician judged that mitiglinide 10 mg t.i.d presented a safety problem, it could be reduced to 5 mg t.i.d.

During both the observation and treatment periods, concomitant use of oral hypoglycemic agents (other than the study drug) and the use of insulin products were prohibited, whereas administration and dosage of drugs used from before the study for treatment of mild-to-moderate complications was not changed whenever possible.

Patient characteristics were examined at screening (week 4). HbA1c, FPG, 1,5-anhydroglucitol (1,5-AG), hematology, blood chemistry and urinalysis values, body weight, and blood pressure were assessed every 4 weeks from week 4 to week 52. Postprandial plasma glucose and postprandial insulin (30 min, 1 h, and 2 h after meal) were measured at weeks 4, 16, 28, and 52. The 400-kcal meal tolerance test at week 4 was performed following administration of a DPP-4 inhibitor or biguanide, and from after week 16 by that of a DPP-4 inhibitor, or biguanide, in combination with mitiglinide.

Study End Points {#Sec5}
----------------

Efficacy end points included: change in HbA1c, 1,5-AG, and FPG at each evaluation point from that measured at week 4 after addition of mitiglinide; therapeutic achievement rate of HbA1c target; and changes in postprandial plasma glucose or postprandial insulin level. Safety end points were incidence rates of adverse events including hypoglycemic episodes and adverse drug reactions. Weight and blood pressure were measured every 4 weeks throughout the study period.

Target Sample Size {#Sec6}
------------------

The number of patients recruited was based on the "Guidelines for Clinical Evaluation of Oral Hypoglycemic Agents" published by the Ministry of Health, Labour and Welfare (MHLW) in 2010 \[[@CR10]\]. The target sample size to evaluate 52 weeks of therapy in each baseline drug combined treatment group was set at ≥50 patients (a total ≥100 patients across the study).

Statistical Analysis {#Sec7}
--------------------

Efficacy end points included PPG (30 min, 1 h, 2 h), postprandial insulin (30 min, 1 h, 2 h), HbA1c, FPG, 1,5-AG, and fasting insulin. For these end points, mean and standard deviation (SD) of the changes at each evaluation time point (value at each evaluation time point − value at baseline) were calculated. Changes over time are shown and compared with baseline using the one-sample *t* test. The HbA1c target achievement rate was evaluated at weeks 12, 28, 40, 52, and/or final evaluation. The HbA1c target achievement rate was calculated as the percentage of patients who achieved an HbA1c of \<7.0% at weeks 12, 28, 40, 52, and/or final evaluation among patients with an HbA1c ≥7.0% at week 0. The insulinogenic index is shown as the median value at each evaluation time point. Safety end points included adverse events and adverse drug reactions (all and hypoglycemia), clinical laboratory tests and physiological parameters. The presence or absence of adverse events and adverse drug reactions (all and hypoglycemia) was assessed in each patient, and the incidence and two-sided 95% confidence intervals were calculated. The incidence and types of adverse events and adverse drug reactions overall and by organ system class were calculated. Totals were calculated for each combined treatment group.

Results {#Sec8}
=======

Analyzed Cases {#Sec9}
--------------

Figure [1](#Fig1){ref-type="fig"} shows the patient characteristics. A total of 191 patients consented to study participation. After a 4-week observation period with administration of DPP-4 inhibitors or biguanides as the baseline drug, mitiglinide was administered to 136 patients who were judged as being eligible for the study (DPP-4 inhibitor CTG, 67 patients; biguanide CTG, 69 patients). Baseline drugs included sitagliptin in 26 patients, vildagliptin in 18, alogliptin in 23, metformin in 66, and buformin in 3.Fig. 1Patient characteristics. *D group* DPP-4 inhibitor combined treatment group, *B group* biguanide combined treatment group

Treatment was discontinued in 26 patients (DPP-4 inhibitor CTG, 9; biguanide CTG, 17) during the study. The reasons for discontinuation from the study were as follows: for DPP-4 inhibitor CTG---adverse events in two patients, inadequate response in five, and other reason in three patients ("at request of patient," "needed to discontinue baseline drug," and "could not return for outpatient visit"); and for biguanide CTG---adverse events were reported in 4 patients, inadequate response in 12, and other reason in 2 patients ("at request by patient" in both). One patient in both of the DPP-4 inhibitor CTG and biguanide CTG had two reasons for discontinuation (adverse event and patient request).

Patient Characteristics {#Sec10}
-----------------------

A total of 136 patients received mitiglinide (DPP-4 inhibitor CTG, 67; biguanide CTG, 69), but after mitiglinide was started, one patient in the biguanide CTG was excluded because of early discontinuation and no evaluable HbA1c. Therefore, the full analysis set included 135 patients (DPP-4 inhibitor CTG, 67; biguanide CTG, 68). Table [1](#Tab1){ref-type="table"} shows the patient characteristics.Table 1Patient characteristicsCharacteristicsTotal (*n* = 135)Mitiglinide/DPP-4 inhibitors (*n* = 67)Mitiglinide/biguanides (*n* = 68)Male, *n* (%)96 (71.1)46 (68.7)50 (73.5)Age (years)58.6 ± 11.160.3 ± 10.656.9 ± 11.5BMI (kg/m^2^)24.85 ± 4.5024.30 ± 4.7125.40 ± 4.25Duration of disease (years)7.6 ± 5.66.7 ± 5.48.5 ± 5.8HOMA-R2.97 ± 2.862.95 ± 3.103.00 ± 2.62HbA1c at 0 weeks (%)7.49 ± 0.607.47 ± 0.547.50 ± 0.66FPG at 0 weeks (mg/dL)148.7 ± 27.4153.7 ± 27.1143.8 ± 27.0PPG 30 min at −4 weeks (mg/dL)228.1 ± 37.6229.2 ± 36.9227.1 ± 38.6PPG 1 h at −4 weeks (mg/dL)268.7 ± 39.7269.2 ± 39.4268.2 ± 40.3PPG 2 h at −4 weeks (mg/dL)245.6 ± 49.5248.1 ± 45.9243.3 ± 53.0Fasting insulin at 0 weeks (μU/mL)7.90 ± 6.687.49 ± 6.558.32 ± 6.82Postprandial insulin 30 min at −4 weeks (μU/mL)21.66 ± 13.8420.08 ± 11.7323.22 ± 15.58Postprandial insulin 1 h at −4 weeks (μU/mL)31.78 ± 21.8628.73 ± 18.2234.79 ± 24.71Postprandial insulin 2 h at −4 weeks (μU/mL)32.14 ± 21.6529.73 ± 20.2534.52 ± 22.85Values are mean ± SD*BMI* body mass index, *FPG* fasting plasma glucose, *Hb1Ac* glycated hemoglobin, *HOMA*-R homeostasis model assessment ratio, *PPG* postprandial plasma glucose

Baseline values (mean ± SD) for the primary efficacy end points of HbA1c, FPG, and 2 h PPG were: DPP-4 inhibitor CTG 7.47 ± 0.54%, 153.7 ± 27.1 mg/dL, and 248.1 ± 45.9 mg/dL, respectively; and biguanide CTG 7.50 ± 0.66%, 143.8 ± 27.0 mg/dL, and 243.3 ± 53.0 mg/dL, respectively. These patients with type 2 diabetes in the DPP-4 inhibitor CTG and biguanide CTG had inadequate glycemic control and were enrolled in the study. BMI distribution before starting treatment (baseline) showed a higher percentage of obese patients (BMI ≥25 kg/m^2^) in the biguanide CTG than in the DPP-4 inhibitor CTG (DPP-4 inhibitor CTG, 31.3%; biguanide CTG, 48.5%).

Efficacy {#Sec11}
--------

In both the DPP-4 inhibitor CTG and the biguanide CTG, a comparison of 30 min, 1 h, and 2 h PPG values between baseline and each evaluation time point (weeks 16, 28 and 52, and final evaluation) showed significant improvement (all with *P* \< 0.001, Table [2](#Tab2){ref-type="table"}). In addition, FPG during early combined treatment (weeks 12--20) showed a significant improvement compared with baseline. Subsequently, in both cohorts there was a deterioration, followed by a trend toward improvement from week 40 until completion of mitiglinide administration (data not shown).Table 2Change in postprandial plasma glucoseItemBaseline drugTimeNumberChangeSD*P* valuePPG 30 min (mg/dL)DPP-4 inhibitors16 weeks65−38.534.9\<0.00128 weeks64−28.032.9\<0.00152 weeks58−37.933.4\<0.001Final65−34.835.5\<0.001Biguanides16 weeks67−28.037.2\<0.00128 weeks65−23.046.2\<0.00152 weeks53−27.639.1\<0.001Final68−22.439.2\<0.001PPG 1 h (mg/dL)DPP-4 inhibitors16 weeks65−51.439.8\<0.00128 weeks64−45.440.0\<0.00152 weeks58−49.737.0\<0.001Final65−46.638.7\<0.001Biguanides16 weeks67−42.338.1\<0.00128 weeks65−40.048.4\<0.00152 weeks53−37.144.7\<0.001Final68−33.044.2\<0.001PPG 2 h (mg/dL)DPP-4 inhibitors16 weeks65−51.850.7\<0.00128 weeks64−50.551.9\<0.00152 weeks58−49.246.7\<0.001Final65−46.347.0\<0.001Biguanides16 weeks67−42.346.7\<0.00128 weeks65−42.356.2\<0.00152 weeks53−39.153.5\<0.001Final68−36.051.6\<0.001*P* value: one-sided *t* test \[vs. before treatment with mitiglinide (−4 weeks)\]*DPP*-*4* dipeptidyl peptidase-4, *PPG* postprandial plasma glucose

In both the DPP-4 inhibitor CTG and biguanide CTG, postprandial insulin levels at each evaluation time point confirmed significant stimulation of insulin secretion at 30 min and 1 h postprandially (Fig. [2](#Fig2){ref-type="fig"}). Fasting insulin levels did not substantially change throughout the study period.Fig. 2Change in postprandial insulin secretion (mean ± SD). **a** DPP-4 inhibitor combined treatment group, **b** biguanide combined treatment group \**P* \< 0.05 vs. −4 weeks

Figure [3](#Fig3){ref-type="fig"} shows the changes in the insulinogenic index in the DPP-4 inhibitor CTG and biguanide CTG. The insulinogenic index (IGI) at week 4 (when patients were treated with a DPP-4 inhibitor or biguanide as monotherapy) was low at 0.17 and 0.15 (median values), respectively. After combined treatment with mitiglinide (at final evaluation), the IGI was 0.59 in the DPP-4 inhibitor CTG and 0.47 in the biguanide CTG. The addition of mitiglinide improved early insulin secretion. In both the DPP-4 inhibitor CTG and biguanide CTG, 1,5-AG was significantly improved at all evaluation time points as compared to baseline (data not shown).Fig. 3Insulinogenic index (median value). Insulinogenic index: Δ insulin (30 min − 0 min)/Δ glucose (30 min − 0 min). **a** DPP-4 inhibitor combined treatment group, **b** biguanide combined treatment group

Table [3](#Tab3){ref-type="table"} shows the changes in HbA1c. Table [4](#Tab4){ref-type="table"} shows the HbA1c \<7.0% achievement rates at weeks 12, 28, 40 and 52, and at final evaluation. HbA1c levels, compared to baseline, were significantly lower at all evaluation time points in the DPP-4 inhibitor CTG and were significantly lower at all evaluation time points, except week 40 and final evaluation, in the biguanide CTG. The HbA1c \<7.0% achievement rate throughout the study period was 41.7--62.2% in the DPP-4 inhibitor CTG and 27.9--43.8% in the biguanide CTG.Table 3Changes in HbA1cTimeMitiglinide/DPP-4 inhibitorsMitiglinide/biguanidesNumberChangeSD*P* valueNumberChangeSD*P* value4 weeks67−0.310.29\<0.00168−0.230.26\<0.0018 weeks66−0.550.37\<0.00168−0.390.41\<0.00112 weeks66−0.600.46\<0.00168−0.410.55\<0.00116 weeks65−0.540.49\<0.00167−0.400.49\<0.00120 weeks65−0.560.56\<0.00167−0.440.57\<0.00124 weeks64−0.580.60\<0.00165−0.440.59\<0.00128 weeks64−0.470.55\<0.00165−0.340.60\<0.00132 weeks63−0.460.56\<0.00163−0.270.640.00136 weeks63−0.340.59\<0.00160−0.190.590.01540 weeks61−0.360.58\<0.00160−0.140.610.07144 weeks60−0.390.61\<0.00158−0.190.620.02148 weeks59−0.400.59\<0.00156−0.220.600.00752 weeks58−0.450.69\<0.00153−0.280.630.001Final67−0.370.69\<0.00168−0.130.760.154Units: %*P* value: one-sided *t* test \[vs. before treatment with mitiglinide (week 0)\]*DDP*-*4* dipeptidyl dipeptidase-4, *Hb1Ac* glycated hemoglobinTable 4HbA1c \<7.0% achievement rateGroupTime (weeks)Number*n*%Mitiglinide/DPP-4 inhibitors12533056.628512549.040482041.752452862.2Final543157.4Mitiglinide/biguanides12482143.828461941.340431227.952361336.1Final481429.2*DPP*-*4* dipeptidyl peptidase-4, *Hb1Ac* glycated hemoglobin

Safety {#Sec12}
------

Table [5](#Tab5){ref-type="table"} shows the incidence of adverse events and adverse drug reactions, including hypoglycemia. The incidence of adverse events was 71.6% (48/67 patients) in the DPP-4 inhibitor CTG and 82.6% (57/69 patients) in the biguanide CTG. Among adverse events, the incidence of hypoglycemia (adverse events) was 3.0% (2/67 patients) in the DPP-4 inhibitor CTG and 2.9% (2/69 patients) in the biguanide CTG. Adverse drug reactions for which a causal relationship to mitiglinide could not be excluded occurred in 6.0% (4/67 patients) in the DPP-4 inhibitor CTG and 5.8 % (4/69 patients) in the biguanide CTG. Hypoglycemia in all cases was judged as an adverse drug reaction by a physician.Table 5Incidence of adverse events and adverse drug reactionsMitiglinide/DPP-4 inhibitors (*n* = 67)Mitiglinide/biguanides (*n* = 69)Total (*n* = 136)Adverse events All71.6 (59.3, 82.0)82.6 (71.6, 90.7)77.2 (69.2, 84.0) Hypoglycemia symptoms3.0 (0.4, 10.4)2.9 (0.4, 10.1)2.9 (0.8, 7.4)Adverse drug reactions All6.0 (1.7, 14.6)5.8 (1.6, 14.2)5.9 (2.6, 11.3) Hypoglycemia symptoms3.0 (0.4, 10.4)2.9 (0.4, 10.1)2.9 (0.8, 7.4)Data are incidence rate and 95% confidence interval*DPP*-*4* dipeptidyl peptidase-4

Adverse events with an incidence ≥5% in the DPP-4 inhibitor CTG included nasopharyngitis, 25.4% (17/67); pharyngitis, 9.0% (6/67); upper respiratory tract infection, 7.5% (5/67); arthralgia, 6.0% (4/67); back pain, 6.0% (4/67); and γ-glutamyltransferase increase, 6.0% (4/67). Adverse events with an incidence ≥5% in the biguanide CTG included nasopharyngitis, 43.5% (30/69); bronchitis, 11.6% (8/69); γ-glutamyltransferase increase 10.1% (7/69); upper respiratory tract infection, 7.2% (5/69) alanine aminotransferase increase, 7.2% (5/69); white blood cell count increase, 7.2% (5/69); dental caries, 5.8% (4/69); and blood urine presence, 5.8% (4/69) (Table [6](#Tab6){ref-type="table"}).Table 6Adverse events and adverse drug reactions with an incidence of ≥5%Adverse eventAdverse drug reactionMitiglinide/DPP-4 inhibitors (*n* = 67)Mitiglinide/biguanides (*n* = 69)Mitiglinide/DPP-4 inhibitors (*n* = 67)Mitiglinide/biguanides (*n* = 69)*n*%*n*%*n*%*n*%Bronchitis23.0811.600.000.0Nasopharyngitis1725.43043.500.000.0Pharyngitis69.022.900.000.0Upper respiratory tract inflammation57.557.200.000.0Dental caries00.045.800.000.0Arthralgia46.011.400.000.0Back pain46.011.400.000.0Alanine aminotransferase increase00.057.200.000.0γ-glutamyltransferase increase46.0710.100.011.4Blood urine present00.045.800.000.0White blood cell count increase34.557.200.000.0*DPP*-*4* dipeptidyl peptidase-4

The number of adverse events by severity was: DPP-4 inhibitor CTG---mild 128, moderate 5, and severe 0 events; biguanide CTG---mild 185, moderate 5, and severe 6 events. Most adverse events were mild or moderate. A causal relationship with mitiglinide was excluded for all the six severe events in the biguanide CTG. In addition, all hypoglycemic events were mild.

One serious adverse event occurred in one patient in the DPP-4 inhibitor CTG: large intestine carcinoma. Nine serious adverse events occurred among five patients in the biguanide CTG: prostate cancer, acute myocardial infarction, brain contusion, skull fracture, traumatic lung injury, rib fracture, lumbar vertebral fracture, colonic polyp, and large intestine carcinoma. A causal relationship with mitiglinide was excluded for all of these serious adverse events. No deaths occurred in the study.

Figure [4](#Fig4){ref-type="fig"} shows the changes in weight in the DPP-4 inhibitor CTG and biguanide CTG. Weight in the DPP-4 inhibitor CTG was: week 0, 64.62 ± 13.97 kg (mean ± SD); week 16, 65.42 ± 14.35 kg; week 28, 66.04 ± 14.64 kg; week 40, 65.75 ± 15.12 kg, week 52, 65.17 ± 14.89 kg; and final evaluation, 65.59 ± 14.37 kg. Weight in the biguanide CTG was: week 0, 70.23 ± 15.30 kg; week 16, 70.81 ± 15.36 kg; week 28, 70.45 ± 14.98 kg; week 40, 71.36 ± 14.39 kg, week 52, 69.42 ± 13.52 kg; and final evaluation, 70.57 ± 15.06 kg. Weight increased slightly during the study period, but by study completion tended to return to baseline levels. Blood pressure showed no significant changes in either the DPP-4 inhibitor CTG or biguanide CTG.Fig. 4Change in weight (mean ± SD). *Top* DPP-4 inhibitor combined treatment group. *Bottom* biguanide combined treatment group

Discussion {#Sec13}
==========

Mitiglinide, a rapid- and short-acting insulinotropic agent, has been used to improve postprandial hyperglycemia in T2DM \[[@CR11]--[@CR13]\]. However, to date, sufficient evidence has not been established for combined treatment with a DPP-4 inhibitor or biguanide. In this study, we investigated the efficacy and safety of mitiglinide for use in combined treatment in Japanese patients with T2DM experiencing inadequate glycemic control with DPP-4 inhibitors or biguanides monotherapy.

With regard to efficacy, in both the DPP-4 inhibitor CTG and biguanide CTG, the addition of mitiglinide significantly stimulated early postprandial insulin secretion, with significant improvement in PPG (30 min, 1 h, and 2 h values) throughout the study period. In general, IGI is often ≤0.4 during a 75-g OGTT in T2DM patients \[[@CR14]\]. In this study, the baseline IGI was as low as 0.15--0.17 (median value), but after mitiglinide administration many patients had an IGI ≥0.4 during a 400-kcal meal tolerance test. These results confirmed an improvement in early postprandial insulin secretion, a characteristic of mitiglinide, even in combined treatment with a DPP-4 inhibitor or biguanide.

A meal tolerance test to evaluate PPG values is time consuming for patients and requires frequent collection of blood samples. Therefore, when compared with HbA1c and FPG, testing for PPG is performed in few patients. However, glycemic control based on HbA1c as a marker alone may not reduce the incidence of macrovascular complications \[[@CR4]--[@CR6]\]. To manage high-quality glycemic control in T2DM patient, it is necessary once again to recognize the clinical importance of improving postprandial hyperglycemia.

Regarding HbA1c as a marker of overall glycemic control, an HbA1c of \<7.0% has been established as a target in terms of preventing diabetic complications \[[@CR14]\]. In this study, at the time of final evaluation, the HbA1c \<7.0% achievement rate was 57.4% in the DPP-4 inhibitor CTG and 29.2% in the biguanide CTG. Although this rate was somewhat low in the biguanide CTG when compared with the DPP-4 inhibitor CTG, the addition of mitiglinide enabled a certain amount of patients to reach this target goal.

In both the DPP-4 inhibitor CTG and biguanide CTG, HbA1c transiently increased after week 28, reached a peak at week 40, and then again improved. The reason was probably a seasonal fluctuation in HbA1c levels, as clinically reported in Japan and overseas \[[@CR12]--[@CR14]\]. These clinical reports have described increased HbA1c levels from the autumn to before spring, with fluctuations of about 0.2--0.3%. In this study, weeks 24--40 in many patients corresponded to the period from autumn to before spring. Considering that the increase in HbA1c was also about 0.2--0.3%, the fluctuation in this study was probably similar to the seasonal fluctuations reported elsewhere \[[@CR15]--[@CR17]\]. These findings again highlight the importance of not only drug therapy, but also dietary and exercise therapy in T2DM.

With regard to safety, the incidence of hypoglycemia, which is generally a concern when using oral glucose-lowering drugs, was 3.0% (2/67 patients) in the DPP-4 inhibitor CTG and 2.9% (2/69 patients) in the biguanide CTG. Thus, the incidence of hypoglycemia was low, and all hypoglycemic symptoms were mild. Body weight increased slightly during the study in both the DPP-4 inhibitor CTG and biguanide CTG, but by completion of treatment tended to revert to baseline levels. This may also be a seasonal fluctuation similar to glycemic control.

This study has two important limitations. Firstly, it was conducted under open label design with no control arm, and therefore it was not possible to eliminate all confounding factors. Secondly, in our study, the variety of DPP-4 inhibitors and biguanides used was limited; the DPP-4 inhibitors were sitagliptin, alogliptin and vildagliptin only, and biguanide buformin was used in only three cases. Therefore, interpretation of our findings requires caution until further studies can be conducted.

Conclusion {#Sec14}
==========

The combination of mitiglinide with DPP-4 inhibitors or biguanides improved postprandial hyperglycemia and HbA1c, as a marker of overall glycemic control, without increasing risk to safety. This therapy is a clinically promising therapeutic strategy for T2DM.
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